
JAGX — Jaguar Animal Health Inc
NASDAQ · Healthcare · Biotechnology
$0.72
-$0.01 (-1.23%)
Jaguar Animal Health Inc (JAGX) is a biotechnology company listed on NASDAQ. It is led by Lisa A. Conte, based in 200 Pine Street, San Francisco, CA, United States, 94104, with about 47 employees. Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Latest reported JAGX revenue for 2026-06-30 was $1.2M. Net income was -$12.8M. Revenue was down 94.0% from 2026-03-31 to 2026-06-30. JAGX currently screens at market cap $1.7M.
Use this JAGX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the JAGX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the JAGX SEC filings page. Lician reads the product cache first so this HTML stays unique to Jaguar Animal Health Inc even when a live quote feed is slow.
About Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
JAGX Key Statistics
Market Cap
$1.67M
Volume
56,366
Previous Close
$0.91
Day Range
$0.87 – $0.97
P/B Ratio
1.62
EPS
-$22.97
Revenue
$11.51M
Net Income
-$53.58M
Gross Profit
$7.74M
Free Cash Flow
$0.00
Revenue Growth
-1.5%
Profit Margin
-465.4%
Debt to Equity
0.00
Employees
47
JAGX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $11.51M | $11.69M |
| Cost of Revenue | $3.77M | $1.96M |
| Gross Profit | $7.74M | $9.73M |
| Operating Income | -$45.91M | -$30.83M |
| Net Income | -$53.58M | -$38.49M |
| EPS (Diluted) | -$22.97 | -$130.69 |
Total Assets
$38.32M
Total Debt
$0.00
Shareholders' Equity
-$18.69M
Cash & Equivalents
$968.00K
Operating Cash Flow
-$23.69M
Free Cash Flow
$0.00
Jaguar Animal Health Inc Company Information
- Founder, CEO, President & Director
- Lisa A. Conte
- Headquarters
- 200 Pine Street, San Francisco, CA, United States, 94104
- Website
- jaguar.health
- Phone
- 415 371 8300
- IPO / Founded
- 2015-05-13
- Sector
- Healthcare
- Industry
- Biotechnology